ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 9
Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.
Video Player is loading.
Video content above is prompted by the following questions:
- After frontline therapy in limited-stage small cell lung cancer (LS-SCLC), how do you determine the appropriate second-line and subsequent therapy?
- What patient-specific factors do you consider?
- Other than clinical trial enrollment, what would you consider for second-line treatment?
- Please briefly describe the SWOG umbrella protocol for ES-SCLC
- Can we personalize treatment by identifying molecular subtypes that may be more responsive to certain therapies than others?
- Please provide your insights on the potential for improved survival benefits with chemoimmunotherapy and consolidative thoracic radiotherapy in patients with ES-SCLC.
- What additional research should be conducted to further validate the use of CIT and cTRT in this patient population?
- Please briefly comment on key updates in SCLC recently presented at ASCO 2024 and discuss how these findings may impact the overall treatment landscape.
